| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M G Murer, J Ferrario, M Delfino, G Dziewczapolski, O S Gershanik, R Raisman-Vozar. Increased [125I]sulpiride binding in the subthalamic nucleus of rats with nigrostriatal lesions. Neuroreport. vol 10. issue 7. 1999-09-16. PMID:10380970. |
our results demonstrate that most stn d2-class dopamine receptors are postsynaptic to afferent dopaminergic fibers. |
1999-09-16 |
2023-08-12 |
rat |
| H Kawakam. [Transporter and neurological disease]. Rinsho shinkeigaku = Clinical neurology. vol 39. issue 1. 1999-09-15. PMID:10377785. |
dopamine transporter of the family takes up 1-methyl-4-phenylpyridinium (mpp+) and causes dopaminergic cell death. |
1999-09-15 |
2023-08-12 |
Not clear |
| B Ferger, O Eberhardt, P Teismann, C de Groote, J B Schul. Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation. Journal of neurochemistry. vol 73. issue 3. 1999-09-14. PMID:10461928. |
prior unilateral lesioning of the nigrostriatal dopaminergic pathway by focal injection of 6-hydroxydopamine blocked the malonate-induced increase in dopamine concentrations and the generation of hydroxyl radicals and attenuated the lesion volume. |
1999-09-14 |
2023-08-12 |
rat |
| M D Lindner, C K Cain, M A Plone, B R Frydel, T J Blaney, D F Emerich, M R Hoan. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behavioural brain research. vol 102. issue 1-2. 1999-09-10. PMID:10403011. |
incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. |
1999-09-10 |
2023-08-12 |
rat |
| M D Lindner, C K Cain, M A Plone, B R Frydel, T J Blaney, D F Emerich, M R Hoan. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behavioural brain research. vol 102. issue 1-2. 1999-09-10. PMID:10403011. |
young (2 months old) and middle-aged (12 months old) rats received bilateral striatal infusions of 6-ohda, over the next 3 months they were assessed with a battery of behavioral tests, and then dopaminergic nigrostriatal cells and striatal dopamine and dopac levels were quantified. |
1999-09-10 |
2023-08-12 |
rat |
| M D Lindner, C K Cain, M A Plone, B R Frydel, T J Blaney, D F Emerich, M R Hoan. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behavioural brain research. vol 102. issue 1-2. 1999-09-10. PMID:10403011. |
akinesia, rigidity, tremor and visuospatial cognitive deficits) can be quantified in rats with incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine levels (2) parkinsonian symptoms were more evident in middle-aged rats with 6-ohda infusions, and (3) there was evidence of substantial neuroplasticity in the older rats, but regardless of the age of the animal, endogenous compensatory mechanisms were unable to maintain striatal dopamine levels after rapid, lesion-induced nigrostriatal cell loss. |
1999-09-10 |
2023-08-12 |
rat |
| M D Lindner, C K Cain, M A Plone, B R Frydel, T J Blaney, D F Emerich, M R Hoan. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behavioural brain research. vol 102. issue 1-2. 1999-09-10. PMID:10403011. |
these results suggest that using older rats with nigrostriatal dopaminergic cell loss and reductions in striatal dopamine levels similar to those in the clinical condition, and measuring behavioral deficits analogous to parkinsonian symptoms, might increase the predictive validity of pre-clinical rodent models. |
1999-09-10 |
2023-08-12 |
rat |
| P A Jose, G M Eisner, R A Felde. Role of dopamine in the pathogenesis of hypertension. Clinical and experimental pharmacology & physiology. Supplement. vol 26. 1999-09-09. PMID:10386248. |
abnormalities of three aspects of the renal dopaminergic system may lead to hypertension: (i) renal production of dopamine; (ii) transduction of the renal vascular dopamine signal; and (iii) transduction of the renal tubular dopamine signal. |
1999-09-09 |
2023-08-12 |
mouse |
| Q Chen, A H Andersen, Z Zhang, A Ovadia, W A Cass, D M Gash, M J Aviso. Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys. Experimental neurology. vol 158. issue 1. 1999-09-09. PMID:10448418. |
these results suggest that fmri can detect changes in dopamine receptor-mediated neuronal sensitivity to dopaminergic agents. |
1999-09-09 |
2023-08-12 |
monkey |
| J R Taylor, J D Elsworth, M S Lawrence, J R Sladek, R H Roth, D E Redmon. Spontaneous blink rates correlate with dopamine levels in the caudate nucleus of MPTP-treated monkeys. Experimental neurology. vol 158. issue 1. 1999-09-09. PMID:10448434. |
blockade of either dopamine (da) d1 or da d2 receptors or da depletion induced by the dopaminergic neurotoxin mptp both decrease spontaneous eye blink rates in monkeys. |
1999-09-09 |
2023-08-12 |
human |
| C J Harmer, G D Phillip. Enhanced dopamine efflux in the amygdala by a predictive, but not a non-predictive, stimulus: facilitation by prior repeated D-amphetamine. Neuroscience. vol 90. issue 1. 1999-09-08. PMID:10188939. |
mesoamygdaloid dopamine efflux increased significantly during the conditioning test session, but not during the control session, and this dopaminergic response was more marked in rats with prior repeated d-amphetamine experience. |
1999-09-08 |
2023-08-12 |
rat |
| M A Verit. Manganese neurotoxicity: a mechanistic hypothesis. Neurotoxicology. vol 20. issue 2-3. 1999-09-03. PMID:10385907. |
selectivity of dopaminergic neurons is dependent upon interactions of mn2+ with dopamine transport and the role of mn2+ as a pro-oxidative toxicant in conjunction with changes in iron concentration. |
1999-09-03 |
2023-08-12 |
Not clear |
| P P Rowell, B T Larso. Ergocryptine and other ergot alkaloids stimulate the release of [3H]dopamine from rat striatal synaptosomes. Journal of animal science. vol 77. issue 7. 1999-09-02. PMID:10438027. |
the results indicate that, in addition to interacting with dopamine receptors, several ergot alkaloids may produce dopaminergic effects by increasing the release of dopamine from central nerve endings. |
1999-09-02 |
2023-08-12 |
rat |
| B S Kirchhof, U Homberg, A R Merce. Development of dopamine-immunoreactive neurons associated with the antennal lobes of the honey bee, Apis mellifera. The Journal of comparative neurology. vol 411. issue 4. 1999-08-31. PMID:10421873. |
this report examines the development of the dopaminergic system in the primary antennosensory centres (antennal lobes) of the brain of the honey bee, apis mellifera, and the effects of dopamine on neurite outgrowth of antennal-lobe neurons in vitro. |
1999-08-31 |
2023-08-12 |
bee |
| C Mora-Ferrer, S Yazulla, K M Studholme, M Haak-Frendsch. Dopamine D1-receptor immunolocalization in goldfish retina. The Journal of comparative neurology. vol 411. issue 4. 1999-08-31. PMID:10421879. |
the gfd1r antiserum displays cross-reactivity to dopamine receptors in a mammal and a nonmammal and should prove useful in future studies of dopaminergic systems. |
1999-08-31 |
2023-08-12 |
rat |
| T P Piepponen, A Honkanen, T Kivastik, A Zharkovsky, A Turtia, J A Mikkola, L Ahte. Involvement of opioid mu1-receptors in opioid-induced acceleration of striatal and limbic dopaminergic transmission. Pharmacology, biochemistry, and behavior. vol 63. issue 2. 1999-08-20. PMID:10371653. |
the role of mu1-opioid receptors in the acceleration of cerebral dopaminergic transmission induced by morphine and the putative mu1-opioid agonist, etonitazene, was studied in rats by measuring the tissue levels of dopamine (da) and its metabolites 3,4-dihydroxyphenylacetic acid (dopac) and homovanillic acid (hva) in the dorsal striatum and nucleus accumbens. |
1999-08-20 |
2023-08-12 |
rat |
| J S Perlmutter, S M Moerlei. PET measurements of dopaminergic pathways in the brain. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). vol 43. issue 2. 1999-08-18. PMID:10429509. |
positron emission tomography (pet) measurements of dopaminergic pathways have revealed several new insights into the role of dopamine in the pathophysiology and pharmacology of brain diseases such as parkinson's disease (pd), dystonia and schizophrenia. |
1999-08-18 |
2023-08-12 |
Not clear |
| M A Sutton, R J Beninge. Psychopharmacology of conditioned reward: evidence for a rewarding signal at D1-like dopamine receptors. Psychopharmacology. vol 144. issue 2. 1999-08-17. PMID:10394990. |
the effects of dopaminergic agents with different mechanisms of action in this paradigm have revealed several interesting dissociations suggesting that a rewarding signal at dopamine d1-like receptors may mediate both the acquisition of rewarding properties by neutral stimuli and their ability to control behavior. |
1999-08-17 |
2023-08-12 |
Not clear |
| P Hertel, G G Nomikos, T H Svensso. Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. European journal of pharmacology. vol 371. issue 2-3. 1999-08-13. PMID:10357252. |
the effects of the alpha2-adrenoceptor antagonist idazoxan on extracellular concentrations of dopamine in major dopaminergic terminal regions in the brain were investigated by means of microdialysis in freely moving rats. |
1999-08-13 |
2023-08-12 |
rat |
| P Hertel, G G Nomikos, T H Svensso. Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. European journal of pharmacology. vol 371. issue 2-3. 1999-08-13. PMID:10357252. |
these data show that the alpha2-adrenoceptor antagonist idazoxan preferentially increases basal dopamine output in the medial prefrontal cortex through a local mechanism, an effect which appears largely independent of dopaminergic neuronal activity. |
1999-08-13 |
2023-08-12 |
rat |